tirzepatide cardiovascular Tirzepatide goes beyond weight loss—supporting heart health, vascular function, and overall metabolic wellness. #Tirzepatide #HeartHealth #MetabolicSupport #Type2Diabetes #CardiovascularHealth #AmaneciaHealth

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

25.71

★★★★☆4.8 (126)

CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS

27.36

★★★★★4.9 (98)

Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

25.20

★★★★★5.0 (157)

❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on

27.40

★★★★★4.7 (84)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky

24.23

★★★★★4.9 (203)

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

22.62

★★★★★5.0 (176)

In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Read the full SURPASS-CVOT trial

21.27

★★★★★4.8 (132)